FACULTY

PRAVIN DUGEL, MD—Co-Chair
Clinical Associate Professor of Ophthalmology
Doheny Eye Institute, Keck School of Medicine
University of Southern California
Los Angeles, California
Managing Partner
Retinal Consultants of Arizona, Ltd
Phoenix, Arizona

CARL REGILLO, MD—Co-Chair
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania

DAVID BOYER, MD
Clinical Professor of Ophthalmology
Keck School of Medicine
University of Southern California
Los Angeles, California
Senior Partner
Retina-Vitreous Associates Medical Group
Beverly Hills, California

KARL CSAKY, MD, PHD
Vitreoretinal Specialist
Texas Retina Associates
T. Boone Pickens Senior Scientist and Director, Macular Degeneration Molecular Laboratory
Retina Foundation of the Southwest
Dallas, Texas

JAY DUKER, MD
Director
New England Eye Center
Professor and Chair
Department of Ophthalmology
Tufts University School of Medicine
Boston, Massachusetts

LEARNING METHOD AND MEDIUM

This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 2.0 hours to complete.

CONTENT SOURCE

This continuing medical education (CME) activity captures content from a series of regional CME meetings held in the summer and fall of 2013.

ACTIVITY DESCRIPTION

The treatment of wet age-related macular degeneration (AMD) has rapidly evolved with the use of anti-vascular endothelial growth factor (VEGF) therapy. Today, treatment of wet AMD is turning toward individualizing therapy. This CME program was developed specifically to address the questions being asked by retina specialists throughout the United States who treat patients with wet AMD. This monograph reflects the current evidence-based understanding of the issues with expert approaches for optimizing patient outcomes where evidence is not yet available.

TARGET AUDIENCE

This educational activity is intended for retina specialists, retina fellows, and comprehensive ophthalmologists caring for patients with wet AMD.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be better able to:

• Evaluate the current evidence on efficacy, safety, and dosing regimens of the anti-vascular endothelial growth factor agents used to treat wet AMD

• Select a treatment strategy for a variety of patients with wet AMD that maintains visual acuity and long-term safety, as well as meets patient preferences

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The New York Eye and Ear Infirmary and MedEdicus LLC. The New York Eye and Ear Infirmary is accredited by the ACCME to provide continuing medical education for physicians.

In July 2013, the Accreditation Council for Continuing Medical Education (ACCME) awarded The New York Eye and Ear Infirmary Institute for Continuing Medical Education “Accreditation with Commendation,” for six years as a provider of continuing medical education for physicians, the highest accreditation status awarded by the ACCME.

AMA CREDIT DESIGNATION STATEMENT

The New York Eye and Ear Infirmary designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GRANTOR STATEMENT

This continuing medical education activity is supported through an unrestricted educational grant from Genentech, Inc.

DISCLOSURE POLICY STATEMENT

It is the policy of The New York Eye and Ear Infirmary that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The New York Eye and Ear Infirmary has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

DISCLOSURES

David Boyer, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerpio Therapeutics; Alcon; Allegro Ophthalmics, LLC; Allergan, Inc; Bausch + Lomb Incorporated; Bayer; Genentech, Inc; GlaxoSmithKline; Merck & Co, Inc; Neurotech Pharmaceuticals; Novartis; Ora, Inc; Pfizer Inc; QLT Inc; and Regeneron Pharmaceuticals, Inc; Fees for promotional, advertising or non-CME services received directly from commercial interest or their Agents (eg, Speakers Bureaus): Allergan, Inc; and Genentech, Inc; Ownership Interest: Allegro Ophthalmics, LLC.

Karl Csaky, MD, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Acucela Inc; Genentech, Inc; GlaxoSmithKline; Merck & Co, Inc; Novartis; Ophthotech; Pfizer Inc; QLT Inc; Roche USA; and Santen Pharmaceutical Co, Ltd; Contracted Research: Genentech, Inc; Fees for promotional, advertising or non-CME services received directly from commercial interest or their Agents (eg, Speakers Bureaus): Genentech, Inc; Ownership Interest: Ophthotech.

Pravin Dugel, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Medical Optics; Alcon, Inc; Alimera Sciences; Allergan, Inc; ArcticDX; Digisight Technologies; Genentech, Inc; Lux Biosciences, Inc; MacuSight, Inc; NeoVista, Inc; Ora, Inc; Ophthotech, Regeneron Pharmaceuticals, Inc; and ThromboGenics NV; Ownership Interest: ArcticDX; MacuSight, Inc; NeoVista, Inc; Ophthotech; and DigiSight Technologies.

Jay Duker, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: EMD Serono, Inc; Novartis Pharmaceuticals Corporation; Optos; QLT Phototherapeutics, Inc; and ThromboGenics NV; Contracted Research: Carl Zeiss Meditec, Inc; and Optovue, Inc; Ownership Interest: EyeNetra; Hemera Biosciences, Inc; Ophthotech; and Paloma Pharmaceuticals, Inc.

Carl Regillo, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Genentech, Inc; GlaxoSmithKline; and Regeneron Pharmaceuticals, Inc; Contracted Research: Genentech, Inc; GlaxoSmithKline; and Regeneron Pharmaceuticals, Inc; Fees for promotional, advertising or non-CME services received directly from commercial interest or their Agents (eg, Speakers Bureaus): Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

PEER REVIEW DISCLOSURE

John Sorenson, MD, has no relevant commercial relationships to disclose.

EDITORIAL SUPPORT DISCLOSURES

Tony Realini, MD, MPH, had a financial agreement or affiliation during the past year with the following commerecial interests in the form of Consultant/Advisory Board: Alcon, Inc; Sensimed; and Sucampo Pharmaceuticals, Inc; Contracted Research: Alcon, Inc; Fees for promotional, advertising or non-CME services received directly from commerical interest or their Agents (eg, Speakers Bureaus): Alcon, Inc; and Lumenis Ltd.

Cynthia Tornallyay, RD, MBA, CCMEP; Kimberly Corbin, CCMEP; Barbara Aubel; and Vivian Fransen, MPA, have no relevant commercial relationships to disclose.

DISCLOSURE ATTESTATION

The contributing physicians listed above have attested to the following:

1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;

2) that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and

3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

OFF-LABEL DISCUSSION

This activity includes off-label discussion of bevacizumab for ophthalmic use. Please refer to the official prescribing information for discussion of approved indications, contraindications, and warnings.

FOR DIGITAL EDITIONS

System Requirements:

If you are viewing this activity online, please ensure the computer you are using meets the following requirements:

• Operating System: Windows or Macintosh

• Media Viewing Requirements: Flash Player or Adobe Reader

• Supported Browsers: Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera

• A good Internet connection

The New York Eye and Ear Infirmary Privacy & Confidentiality Policies

CME policies: http://www.nyee.edu/cme-enduring.html

Hospital policies: http://www.nyee.edu/website-privacy.html

CME Provider Contact Information

For questions about this activity, call 212-979-4383.

TO OBTAIN AMA PRA CATEGORY 1 CREDIT™

To obtain AMA PRA Category 1 Credit™ for this activity, read the material in its entirety and consult referenced sources as necessary. Complete the evaluation form along with the post test answer box within this supplement. Remove the Activity Evaluation/Credit Request page from the printed supplement or print the Activity Evaluation/Credit Request page from the Digital Edition. Return via mail to Kim Corbin, Director, ICME, The New York Eye and Ear Infirmary, 310 East 14th Street, New York, NY 10003 or fax to (212) 353-5703. Your certificate will be mailed to the address you provide on the evaluation form. Please allow 3 weeks for Activity Evaluation/Credit Request forms to be processed. There are no fees for participating in and receiving CME credit for this activity.

Alternatively, we offer instant certificate processing and support Green CME. Please take this post test and evaluation online by going to http://tinyurl.com/TopQuestionsWetAMD. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The New York Eye and Ear Infirmary, MedEdicus LLC, Genentech, Inc., or Retinal Physician.

This CME activity is copyrighted to MedEdicus LLC ©2013. All rights reserved.